Matches in Nanopublications for { ?s ?p ""Risedronate Sodium is contraindicated in patients with the following conditions: Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia [ see Warnings and Precautions ( 5.1 ) Inability to stand or sit upright for at least 30 minutes [ see Dosage and Administration ( 2 ), Warnings and Precautions ( 5.1 ) Hypocalcemia [ see Warnings and Precautions ( 5.2 ) Known hypersensitivity to Risedronate Sodium or any of its excipients. Angioedema, generalized rash, bullous skin reactions, Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported [ see Adverse Reactions ( 6.2 ) Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia ( 4 5.1 Inability to stand or sit upright for at least 30 minutes ( 4 5.1 Hypocalcemia ( 4 5.2 Known hypersensitivity to any component of this product ( 4 6.2"" ?g. }
Showing items 1 to 1 of
1
with 100 items per page.
- association label ""Risedronate Sodium is contraindicated in patients with the following conditions: Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia [ see Warnings and Precautions ( 5.1 ) Inability to stand or sit upright for at least 30 minutes [ see Dosage and Administration ( 2 ), Warnings and Precautions ( 5.1 ) Hypocalcemia [ see Warnings and Precautions ( 5.2 ) Known hypersensitivity to Risedronate Sodium or any of its excipients. Angioedema, generalized rash, bullous skin reactions, Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported [ see Adverse Reactions ( 6.2 ) Abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia ( 4 5.1 Inability to stand or sit upright for at least 30 minutes ( 4 5.1 Hypocalcemia ( 4 5.2 Known hypersensitivity to any component of this product ( 4 6.2"" assertion.